In the U.K. hospital study, the AI device demonstrated sensitivity for malignancy exceeding 97% across all skin cancer types and achieved a specificity of 72.1%.

Overview Debates Related claims Topics Sources

Barrister Peter Mant KC stated at the Lampard Inquiry that clinical effectiveness claims made by Oxevision manufacturer Lio Health were based on unverified anecdotes and unbacked by statistical evidence.

Swedish researchers tested the Dermalyser AI smartphone app across 36 primary care centers from May to December 2022, evaluating 253 suspicious skin lesions in 228 patients.

Researchers trained and validated the FAHR-Face survival prediction tools using photographs of over 30,000 cancer patients with known medical outcomes.

In the Swedish primary care trial, the Dermalyser app achieved an overall area under the ROC curve of 0.960 with 95.2% sensitivity and 84.5% specificity for distinguishing melanoma.

The FAHR-FaceAge tool demonstrated biological age estimation correlation scores across racial groups of 0.86 for White, 0.81 for Black, 0.86 for Asian, and 0.91 for Hispanic individuals.

FAHR-FaceAge and FAHR-FaceSurvival yield weakly correlated predictions, and combining both measures improved survival-model fit in external validation testing.

Researchers validated the FAHR-FaceSurvival prediction model in an external cohort of nearly 4,900 cancer patients in the Netherlands.

In a validation trial of 3,820 cancer patients, 64 of the 122 patients assigned the highest FAHR-FaceSurvival risk scores died within 90 days, compared to 20 of 975 in the lowest-risk group.

University of Surrey machine learning expert Prof. Miroslaw Bober cautioned that the technology remains a proof of concept that requires further testing across hospitals before clinical deployment.

When evaluated against the AI model TotalSegmentator, the Percival model flagged conditions including pancreatic cancer, cirrhosis, and bacterial pneumonia significantly more reliably.

The findings and technical specifications regarding the Percival model were published by lead author Cameron A. Beeche and senior author Walter Witschey in the journal npj Digital Medicine.

The Tanzanian diabetic retinopathy trial results were published in The Lancet Global Health by lead author Dr. Charles R. Cleland and research colleagues.

A study by the London School of Hygiene & Tropical Medicine evaluated 2,378 people across 24 hospitals in Tanzania to compare AI-supported diabetic retinopathy screening against standard pathways.

The U.S. Department of Energy plans to invest more than $500 million over five years in biological measurement, modeling, and computing for the Virtual Biology Initiative

The Virtual Biology Initiative, partnering with Chan Zuckerberg Biohub, the U.S. Department of Energy, the National Institutes of Health, Google DeepMind, Isomorphic Labs, and Meta Platforms, aims to build open datasets for a virtual cell predicting cellular behavior

The Virtual Biology Initiative involves a total investment of $1.8 billion in funding, data, computing, and biological measurement technology

Google DeepMind, Isomorphic Labs, and Meta Platforms are collectively investing $300 million in the Virtual Biology Initiative, while the Chan Zuckerberg Biohub previously committed $500 million in April 2026

Public-private partnerships are the most effective way to build foundational scientific datasets

The US government's $500 million investment in AI biological modeling is justified

According to Chan Zuckerberg Biohub head of science Alex Rives, current cell datasets contain hundreds of millions of cells, but an accurate predictive model will require billions and eventually trillions of cells